Holen Sie sich die Stockscreener-App
84.85
5.25%
-4.70
Schlusskurs vom Vortag:
$89.55
Offen:
$89.71
24-Stunden-Volumen:
1.05M
Relative Volume:
0.60
Marktkapitalisierung:
$7.04B
Einnahmen:
$1.73B
Nettoeinkommen (Verlust:
$682.64M
KGV:
10.97
EPS:
7.7364
Netto-Cashflow:
$411.18M
1W Leistung:
+1.85%
1M Leistung:
+15.68%
6M Leistung:
+9.44%
1J Leistung:
+71.34%
1-Tages-Spanne:
$83.83
$89.71
1-Wochen-Bereich:
$82.70
$90.87
52-Wochen-Spanne:
$43.17
$90.87
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Firmenname
Ptc Therapeutics Inc
Sektor
Branche
Telefon
(908) 222-7000
Adresse
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
84.85 | 7.04B | 1.73B | 682.64M | 411.18M | 7.7364 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Raymond James | Outperform |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2025-12-01 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-17 | Eingeleitet | Truist | Buy |
| 2025-05-09 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-07 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-11 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-12-13 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-09-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-08-26 | Fortgesetzt | UBS | Buy |
| 2024-05-20 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-30 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Herabstufung | Citigroup | Neutral → Sell |
| 2023-10-06 | Herabstufung | Truist | Buy → Hold |
| 2023-09-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-09-15 | Herabstufung | Raymond James | Outperform → Underperform |
| 2023-03-17 | Eingeleitet | SVB Securities | Market Perform |
| 2022-12-14 | Eingeleitet | Goldman | Sell |
| 2022-09-12 | Eingeleitet | Jefferies | Buy |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-29 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-30 | Herabstufung | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-04-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-02-20 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-05-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Eingeleitet | Bernstein | Outperform |
| 2018-10-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-06-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Ptc Therapeutics Inc Aktie (PTCT) Neueste Nachrichten
PTC Therapeutics (PTCT) Q3 2024 earnings summary - Quartr
PTC Therapeutics (PTCT) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
PTC Therapeutics (PTCT) Q2 2024 earnings summary - Quartr
PTC Therapeutics (PTCT) Stock May Be Fully Priced After Rare Disease Data - Yahoo Finance
Reasons why investors should consider betting on PTC stock now - MSN
Is PTC Therapeutics (PTCT) A Bargain Following Its Russell 2000 Defensive Index Additions? - Yahoo Finance UK
PTC Therapeutics Drops 5.5% Amid Sector-Wide Selling - AlphaStreet
Reasons Why Investors Should Consider Betting on PTC Stock Now - Yahoo Finance
PTCT (NASDAQ: PTCT) affiliate sale notice — Form 144 - Stock Titan
Form 144 PTC THERAPEUTICS For: 9 July By Investing.com - Investing.com Australia
Stocks Look Shaky, But This Sector is Booming (Biotech) - Yahoo Finance
[144] PTC THERAPEUTICS, INC. SEC Filing - Stock Titan
Responsive Playbooks and the PTCT Inflection - Stock Traders Daily
Ptc therapeutics tech ops chief sells $4.1m in common stock By Investing.com - Investing.com India
Form 4 PTC Therapeutics Inc For: 8 July By Investing.com - Investing.com Nigeria
PTC Therapeutics Inc. (PTCT) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Barclays Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $120 - Moomoo
PTC Therapeutics(PTCT.US) Officer Sells US$4.09 Million in Common Stock - Moomoo
Ptc therapeutics tech ops chief sells $4.1m in common stock - Investing.com
PTC Therapeutics’ Mark Boulding, exec VP, sells $432,117 in stock - Investing.com
PTC Therapeutics’ Mark Boulding, exec VP, sells $432,117 in stock By Investing.com - Investing.com Canada
PTC Therapeutics (PTCT) officer sells shares after exercising options - Stock Titan
PTC Therapeutics (PTCT) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance Australia
PTC Therapeutics Jumps 5.1% Amid Sector-Wide Rally - AlphaStreet
Form 144 PTC THERAPEUTICS For: 7 July By Investing.com - Investing.com Nigeria
PTCT (NASDAQ: PTCT) — 24,613 shares reported for sale after option exercise - Stock Titan
PTCT Maintains Rating by RBC Capital -- Price Target Raised to $85 - GuruFocus
Ptc Therapeutics stock hits all-time high of 87.56 USD - Investing.com
Ptc Therapeutics stock hits all-time high of 87.56 USD By Investing.com - Investing.com Canada
PTC Therapeutics weighs strategy amid rare disease focus - Ad-hoc-news.de
RBC Capital Adjusts PTC Therapeutics Price Target to $85 From $82, Maintains Sector Perform Rating - Moomoo
Does Triple Russell 2000 Defensive Index Inclusion Reframe PTC Therapeutics’ Risk Profile And Rare-Disease Story (PTCT)? - simplywall.st
Form 144 PTC THERAPEUTICS For: 6 July By Investing.com - Investing.com South Africa
PTCT (NASDAQ) insider sales: 50,162 shares in June; option exercise 07/06/2026 - Stock Titan
PTCT (NASDAQ) affiliate plans option exercise; director sold 10,522 shares - Stock Titan
All eyes on PTC Therapeutics earnings after brutal Q4 miss - Investing.com
Enterprise value to EBIT forward of PTC Therapeutics, Inc. – NASDAQ:PTCT - TradingView
PTC Therapeutics updates investors on rare disease pipeline as Nasdaq-listed biotech advances progra - AD HOC NEWS
CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data - TradingView
PTC Therapeutics Inc (PTCT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Ptc therapeutics chief technical ops officer sells $693k in stock By Investing.com - Investing.com Australia
Ptc therapeutics chief technical ops officer sells $693k in stock - Investing.com Australia
Form 4 PTC Therapeutics Inc For: 30 June By Investing.com - Investing.com South Africa
Enterprise value to EBITDA forward of PTC Therapeutics, Inc. – NASDAQ:PTCT - TradingView
Price to sales forward of PTC Therapeutics, Inc. – NASDAQ:PTCT - TradingView
Enterprise value to revenue forward of PTC Therapeutics, Inc. – NASDAQ:PTCT - TradingView
PTC Therapeutics, Inc.(NasdaqGS: PTCT) added to Russell 2000 Value-Defensive Index - marketscreener.com
PTC Therapeutics, Inc.(NasdaqGS: PTCT) added to Russell 2000 Growth-Defensive Index - marketscreener.com
Price to earnings forward of PTC Therapeutics, Inc. – HAM:BH3 - TradingView
Price to earnings forward of PTC Therapeutics, Inc. – FWB:BH3 - TradingView
PTC Therapeutics, Inc.(NasdaqGS: PTCT) added to Russell 2000 Defensive Index - marketscreener.com
Finanzdaten der Ptc Therapeutics Inc-Aktie (PTCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):